Program
Rabeprazole
Also written as “rabeprazole”, “rabeprazole sodium” and “E3810”.
Its studies are mostly in Gastroesophageal Reflux · Esophagitis, Peptic · Gastrointestinal Diseases · Stomach Ulcer · Heartburn, led by 13 companies.
Drug pageRabeprazole: every studyMany companies study it; this page follows only the 56 they lead. All 105 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eisai | 210 open or running | phase 3since Sep 12, 2005 | Aug 19, 2005 | none ahead |
| Johnson & Johnsonits history only | 150 open or running | phase 4since Sep 13, 2005 | Sep 13, 2005 | none ahead |
| Pfizerits history only | 40 open or running | phase 1since Mar 24, 2014 | Mar 24, 2014 | none ahead |
| GlaxoSmithKlineits history only | 30 open or running | phase 4since May 14, 2015 | Sep 26, 2013 | none ahead |
| Viatrisits history only | 30 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| Lomond Therapeuticsits history only | 20 open or running | phase 1since May 1, 2024 | May 1, 2024 | none ahead |
| Torrent Pharmaceuticalsits history only | 20 open or running | phase 1since Nov 15, 2013 | Nov 15, 2013 | none ahead |
| Boehringer Ingelheimits history only | 10 open or running | phase 1since May 16, 2022 | May 16, 2022 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 10 open or running | phase 4since May 20, 2013 | May 20, 2013 | none ahead |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Jun 15, 2015 | Jun 15, 2015 | none ahead |
| Neutec Ar-Ge San ve Tic A.Şits history only | 10 open or running | phase 4since Feb 10, 2016 | Feb 10, 2016 | none ahead |
| PriCara, Unit of Ortho-McNeilits history only | 10 open or running | phase 4since Oct 7, 2005 | Oct 7, 2005 | none ahead |
| Yungjin Pharm.its history only | 10 open or running | phase 1since Jan 7, 2021 | Jan 7, 2021 | none ahead |
Also a collaborator on its studies: Ono Pharmaceutical and Pierre Fabre Laboratories.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Eisai only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 19, 2005First study: phase 2 study in Gastroesophageal RefluxFirst studyNCT00132496 · 111 enrolled · United States
- Sep 12, 20052 phase 3 studies in Non-erosive Gastroesophageal Reflux DiseaseNCT00165672, NCT00165646
- Sep 13, 2005Phase 2 study in Gastroesophageal RefluxNCT00165841 · 200 enrolled · United States
- Oct 10, 20052 phase 3 studies in HeartburnNCT00236197, NCT00236184
- Apr 9, 20083 phase 3 studies in Gastroesophageal RefluxNCT00658775, NCT00658632, NCT00658528
- Oct 9, 2008Phase 3 study in Esophagitis, PepticNCT00770913 · 337 enrolled · Japan
- Feb 5, 20092 phase 3 studies in Gastroesophageal RefluxNCT00839306, NCT00838526
- May 29, 2009Phase 3 study in Gastroesophageal RefluxNCT00911534 · 305 enrolled · United States
- Mar 11, 20102 phase 1 studies in HealthyNCT01085708, NCT01085695
- Mar 17, 2010Phase 2 study in DyspepsiaNCT01089543 · 338 enrolled · Japan
- Jun 28, 2010Phase 1 study in HealthyNCT01153659 · 90 enrolled · United States
- Sep 14, 2010Phase 2 study in HealthyNCT01202071 · 24 enrolled · Japan
- Jul 18, 20112 phase 3 studies in Stomach UlcerNCT01398410, NCT01397448
- Mar 24, 2014Phase 3 study in Gastroesophageal RefluxNCT02135107 · 517 enrolled · Japan
TargetBeta
“Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Esomeprazolerule | AstraZeneca | phase 4 | 129 |
| Omeprazolerule | AstraZeneca | phase 4 | 56 |
| tegoprazanrule | HK inno.N | phase 4 | 48 |
| vonoprazanrule | Takeda | phase 4 | 48 |
| fexuprazanrule | Daewoong Pharmaceutical | phase 4 | 29 |
Studies
All 21 Eisai leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02135107Gastroesophageal Reflux · Japan | 3 | Completed | May 2016 | 517 |
| NCT01398410Stomach Ulcer · Japan | 3 | Completed | Dec 2013 | 405 |
| NCT01397448Stomach Ulcer · Japan | 3 | Completed | Mar 2013 | 472 |
| NCT01202071Healthy · Japan | 2 | Completed | Dec 2010 | 24 |
| NCT01153659Healthy · United States | 1 | Completed | Aug 2010 | 90 |
| NCT01089543Dyspepsia · Japan | 2 | Completed | Aug 2011 | 338 |
| NCT01085708Healthy | 1 | Completed | May 2010 | 16 |
| NCT01085695Healthy | 1 | Completed | May 2010 | 16 |
| NCT00911534Gastroesophageal Reflux · United States | 3 | Completed | Jul 2009 | 305 |
| NCT00839306Gastroesophageal Reflux · United States | 3 | Completed | Aug 2009 | 240 |
| NCT00838526Gastroesophageal Reflux · United States | 3 | Completed | Jul 31, 2009 | 240 |
| NCT00770913Esophagitis, Peptic · Japan | 3 | Completed | Nov 2009 | 337 |
| NCT00658775Gastroesophageal Reflux · United States, Argentina, Australia and more | 3 | Completed | Sep 2009 | 1,069 |
| NCT00658632Gastroesophageal Reflux · United States | 3 | Completed | Apr 2009 | 1,397 |
| NCT00658528Gastroesophageal Reflux · United States, Argentina, Australia and more | 3 | Completed | Sep 2009 | 1,061 |
| NCT00236197Heartburn · United States | 3 | Completed | Mar 2006 | 619 |
| NCT00236184Heartburn · United States | 3 | Completed | Mar 2006 | 629 |
| NCT00165841Gastroesophageal Reflux · United States | 2 | Completed | Dec 2005 | 200 |
| NCT00165672Non-erosive Gastroesophageal Reflux Disease · Japan | 3 | Completed | Oct 2005 | 26 |
| NCT00165646Non-erosive Gastroesophageal Reflux Disease · Japan | 3 | Completed | Oct 2005 | 288 |
| NCT00132496Gastroesophageal Reflux · United States | 2 | Completed | May 2006 | 111 |
How it is read
Names in the registry
- “Rabeprazole”, 15 entries
- “rabeprazole”, 14 entries
- “rabeprazole sodium”, 10 entries
- “E3810”, 8 entries
- “Rabeprazole sodium”, 6 entries
Conditions, from the studies’ own filings
- Gastroesophageal Reflux, 25 studies
- Esophagitis, Peptic, 3 studies
- Gastrointestinal Diseases, 2 studies
- Stomach Ulcer, 2 studies
- Heartburn, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.